Basaloid-Squamous Carcinoma of the Esophagus Treated by Preoperative Chemotherapy: Report of Two Cases

Abstract

Basaloid squamous carcinoma (BSC) of the esophagus has been associated with a poor outcome after surgery. We herein report two patients with esophageal BSC treated by preoperative chemotherapy. Patient 1 was a 55-year-old man who presented with a tumor of the middle esophagus diagnosed as BSC. He was treated by chemotherapy using a combination of 5-fluorouracil (5-FU: 750 mg/m(2), 1st-5th day, 24-h continuous infusion) and cisplatin (CDDP: 75 mg/m(2), 1st day, drip infusion per 2 h) before surgery, because of lymph node metastases of the mediastinum and around the left gastric artery. Even though the metastatic nodes were reduced and an esophagectomy was performed, the patient died of recurrence 12 months after chemotherapy. Patient 2 was a 57-year-old man who demonstrated BSC of the esophagus with direct invasion to the discending aorta, who was treated by preoperative chemotherapy using the same regimen as that of patient 1. The esophageal tumor was reduced, and a curative esophagectomy was performed. The patient is now alive without recurrence 38 months after chemotherapy. In conclusion, preoperative chemotherapy using a combination of 5-FU and CDDP may thus be an effective treatment for patients with advanced BSC of the esophagus.

p63 Immunohistochemistry in the distinction of adenoid cystic carcinoma from basaloid squamous cell carcinoma

“…Basaloid squamous cells carcinoma is treated with surgery, radiotherapy, or both, with or without chemotherapy (5-fluorouracil and cisplatin). [2][3][4] p63 was discovered in a screen for p53-homologous genes. Like p53, p63 codes for proteins with an amino(N)-terminal transcription-activating region, a middle DNA-binding region, and a carboxyl terminal region responsible for oligomerization.…”

Preoperative chemoradiotherapy and surgery for locally advanced esophageal basaloid squamous carcinoma: report of successful

“…Since Yamamoto et al reported the first case of BSC of the esophagus in 1979 [2], approximately 60 cases of BSC have been reported, mainly from Japanese institutions [3][4][5][6][7][8]. The prognosis of BSC is poor, but it remains controversial compared with SCC.…”

“…In the case of superficial-type BSC having invaded the submucosal layer, the therapeutic effectiveness of surgery alone was reported for some cases [4,5]. Advanced cases of BSC accounting for most patients result in dismal outcomes owing to high rates of rapid and widespread nodal and organ metastases, regardless of curative resection or adjuvant therapy [4,6,8,9]. Sarbia et al reported that there is no difference in the overall survival rate between typical BSC and SCC, being 38.5% and 39.3% after 2 years and 19.2% and 19.0% after 5 years, respectively [10].…”

“…On the other hand, Zhang et al described that the severe survival rate of BSC was 20% after 2 years for resected 16 patients treated with or without adjuvant chemotherapy [9]. In general, locally advanced BSC is regarded as a therapeutically resistant disease associated with a poor prognosis [3][4][5][6][7][8][9].…”

Carcinoma basalóide escamoso: uma forma rara e agressiva de câncer do esôfago e revisão da literatura

“…Autores japoneses preconizam quimioterapia com 5-Fluoracil e cisplatina para os tumores localmente avançados, sem metástases à distância 4,7 . Esta conduta visa reduzir as dimensões da lesão primária, de modo a viabilizar a realização da esofagectomia associada a linfadenectomia em três campos: cervical, torácico e abdominal, com razoável índice de sobrevida.…”